Table 1 Baseline characteristics of patients in the development and validation cohorts
Variables | Development Cohort (n = 656) | Validation Cohort (n = 280) | P-value |
|---|---|---|---|
Age, years, mean (SD) | 58 (18) | 57 (18) | 0.445 |
Male, n (%) | 445 (68) | 193 (69) | 0.742 |
SCr baseline measures, μmol/L, median (IQR) | 85 (62–131) | 80 (58–118) | 0.264 |
Age > 70, n (%) | 173 (26) | 66 (24) | 0.547 |
Hypertension, n (%) | 213 (32) | 97 (35) | 0.518 |
Diabetes, n (%) | 120 (18) | 43 (15) | 0.278 |
Chronic kidney disease, n (%) | 50 (8) | 24 (9) | 0.622 |
Chronic liver disease, n (%) | 73 (11) | 35 (13) | 0.547 |
Chronic pulmonary disease, n (%) | 144 (22) | 68 (24) | 0.435 |
Coronary heart disease, n (%) | 42 (6) | 20 (7) | 0.677 |
Cancer, n (%) | 143 (22) | 63 (23) | 0.813 |
Acute pancreatitis, n (%) | 75 (11) | 36 (13) | 0.537 |
Severe empyrosis, n (%) | 8 (1) | 4 (1) | 0.795 |
Trauma, n (%) | 162 (25) | 56 (20) | 0.120 |
Cardiac failure, n (%) | 196 (30) | 74 (26) | 0.286 |
Respiratory failure, n (%) | 310 (47) | 122 (44) | 0.300 |
Sepsis, n (%) | 154 (23) | 61 (22) | 0.574 |
Shock, n (%) | 273 (42) | 122 (44) | 0.579 |
Cardiopulmonary arrest, n (%) | 52 (8) | 15 (5) | 0.163 |
Anemia, n (%) | 530 (81) | 218 (78) | 0.305 |
Hypoproteinemia, n (%) | 456 (70) | 197 (70) | 0.797 |
pH ≤ 7.30, n (%) | 104 (16) | 40 (14) | 0.543 |
CK > 1000 U/L, n (%) | 200 (30) | 77 (28) | 0.359 |
Nephrotoxin exposure, n (%) | 131 (20) | 69 (25) | 0.110 |
Major surgery, n (%) | 408 (62) | 180 (64) | 0.545 |
Blood transfusion, n (%) | 330 (50) | 133 (48) | 0.432 |
Receiving RRT, n (%) | 113 (17) | 50 (18) | 0.816 |
Mortality, n (%) | 213 (32) | 84 (30) | 0.457 |